Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2002-01-29
2004-08-10
Ungar, Susan (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S810000, C530S387100
Reexamination Certificate
active
06773890
ABSTRACT:
BACKGROUND OF THE INVENTION
Gastric cancer worldwide is the second highest cause of death from cancer. While rates of gastric cancer have been decreasing in the United States, gastric cancer prevalence remains high in other parts of the world, especially in Asia. Presently, patients in endemic regions for gastric cancer, especially Japan and China, undergo screening by upper endoscopy. There is no alternative at present for discovery of early cancer other than by endoscopy. Grading of these endoscopies is based solely on hematoxylin and eosin staining. There are no prognostic markers that could indicate those at risk for future cancer development. Therefore, while biopsies can reveal early gastric cancers, patients in high risk regions who are initially negative by endoscopy must be followed with endoscopies in rule out future developments.
The epidemiological association between chronic
H. pylori
infection and gastric carcinoma is now well established, such that the Working Group Meeting of the International Agency for Research on Cancer with the World Health Organization recently classified
Helicobacter pylori
as a group 1 human gastric carcinogen (Peura, D. A.
Gatroenterology
. 113, S4-S8 (1997)). Parsonnet and colleagues reported that 84% of patients with gastric cancer had serum antibodies against
H. pylori
, as opposed to 66% of uninfected matched controls (Parsonnet, et al.
New Eng. J. Med
. 325, 1127-1131 (1991)).
H. pylori
infection induces a chronic gastritis progressing to atrophic gastritis, foveolar hyperplasia and intestinal metaplasia (Mobley, H. T. L.
Gastronenterology
. 113, S21-S28 (1997)). Recent studies have indicated that chronic gastritis associated with
Helicobacter pylori
contributes to the development of gastric adenocarcinoma (Peura, D. A.
Gatroenterology
. 113, S4-S8 (1997); Parsonnet, et al.
New Eng. J. Med
. 325, 1127-1131 (1991); Forman et al.
Br. J. Med
. 302, 1302-1305 (1991); Nomura, et al.
New Eng. J. Med
. 325, 1132-1136 (1991)). Nevertheless, the mechanism of progression from chronic gastritis to malignant disease remains unclear, and the relationship of intestinal metaplasia,
H. pylori
infection and the development of cancer continues to be controversial. Moreover, while an association between gastric cancer and infection with
H. pylori
has recently been established, the cell of origin for gastric adenocarcinoma is controversial. This does not establish a mechanism between the bacteria and the cancer, and provides little or no guidance for correlating treatment of, or risk associated with,
H. pylori
as it relates to development of gastric cancer.
It is therefore an object of the present invention to provide screening methods for early gastric cancer.
It is a further object of the present invention to provide means for assessing the degree of early gastric cancer and for screening and following patients at risk for gastric cancer.
It is a still further object of the present invention to provide means for serological testing for patients at risk of gastric cancer.
SUMMARY OF THE INVENTION
It has been determined that a specific metaplastic lineage that contains immunoreactivity for a trefoil polypeptide, spasmolytic peptide, is associated with and gives rise to the vast majority of human adenocarcinomas. The identification of this Spasmolytic Polypeptide Expressing Metaplasia (SPEM) is a major factor for grading of biopsies of the stomach to assess risk for gastric cancer. It also forms the basis of a method for serological screening for those at risk for gastric cancer. In a preferred embodiment, antibodies to spasmolytic peptide (hSP) are used in immunostaining of biopsies of gastric tissue obtained by endoscopy for grading biopsies. Those patients having these cells, characterized by a morphology more typical of a type of cell present normally in the intestine and not stomach, Brunner's gland cells, are at risk of developing adenocarcinoma. Since these cells express hSP, antibodies or nucleic acid probes hybridizing to mRNA encoding hSP, can be used for rapid detection of the cells in tissue biopsies. The antibodies can also be used in serological tests for screening and following patients at risk for gastric cancer. In combination with evidence of previous or present invention with
H. pylori
, the tests are predictive of the likelihood of developing adenocarcinoma.
REFERENCES:
patent: 5567594 (1996-10-01), Calenoff
patent: 5783416 (1998-07-01), Thim et al.
patent: 196 29 938 (1997-11-01), None
patent: WO 96/15456 (1996-05-01), None
Hirose et al, (Gann, 1976, 67:(3):355-364).*
Suzuki et al (I To Cho, 1980, 15:*
Tomado (Fukoka Act Med., 1983, 74:366-382).*
Ahnen, et al., “The ulceration-associated cell lineage (UACL) reiterates the Brunner's gland differentiation programme but acquires the proliferative organization of the gastric gland,”J. Pathol.173: 317-326 (1994).
Alison, et al., “Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach,”J. Pathol.175: 405-414 (1995).
Babyatsky, et al., “Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats,”Gastroenterology110: 489-497 (1996).
Beck, et al., “Cloning of contiguous genomic fragments from human chromosome 21 harbouring three trefoil peptide genes,”Hum Genet98(2): 233-235 (1996).
Bluth, et al., “Immunolocalization of transforming growth factor-alpha in normal and diseased human gastric mucosa,”Hum. Pathol.26: 1333-1340 (1995).
Correa, P., “A human model of gastric carcinogenesis,”Cancer Res.48: 3554-3560 (1988).
Dempsey, et al., “Possible role of transforming growth factor alpha in the pathogenesis of Menetrier's disease: supportive evidence from humans and transgenic mice,”Gastroenterology103: 1950-1963 (1992).
DHI Conference on H pylori,Gastroenterolgy113:S4-S8 (1997).
Dixon, et al., “Classification and grading of gastritis. The updated Sydney System.”Am. J. Surg. Pathol.20:1161-1181 (1996).
Elia, et al., “The production and characterization of a new monoclonal antibody to the trefoil peptide human spasmolytic polypeptide,”Histochem. J.26: 644-647 (1994).
Filipe, et al., “Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia,”Int. J. Cancer57: 324-329 (1994).
Fox, et al., “Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice,”Gastroenterology110: 155-166 (1996).
Goldenring, et al., “Expression of trefoil peptides in the gastric mucosa of transgenic mice overexpressing transforming growth factor-alpha,”Growth Factor13(1-2): 111-119 (1996).
Haggitt, “Barrett's esophagus, dysplasia, and adenocarcinoma,”Hum. Pathol.25: 982-993 (1994).
Hanby, et al., The expression of the trefoil peptides pS2 and Human spasmolytic polypeptide (hSP) in ‘Gastric Metaplasia’ of the proximal duodendum: implications for the nature of ‘Gastric Metaplasia’,J. Path.169:355-360 (1993).
Itoh, et al., “cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis,”Biochem. J.318(Pt 3): 939-944 (1996).
Konturek, et al., “Activationof genes for spasmolytic peptide, transforming growth factor alpha and for cyclooxygenase (COX)-1 and COX-2 during gastric adaptation to aspirin damage in rats,”Aliment. Pharmacol. Ther.12(8): 767-777 (1998).
Konturek, et al., “Role of spasmolytic polypeptide in healing of stress-induced gastric lesions in rats,”Regul. Pept.68(1): 71-79 (1997).
Lee, et al., “A small animal model of human Helicobacter pylori active chronic gastritis,”Gastroenterology99: 1315-1323 (1990).
Lefebvre, et al., “Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein,”Science274: 259-262 (1996).
Majumdar, et al., “Localization and significance of pp55, a gastric mucosal membrane protein with tyrosine kinase activity,”Am. J. Physiol.274(5, 1): G863-870 (1998).
McKenzie, et al., “Pancreatic spasmolytic polypeptide protects the gastric mucosa but
Goldenring James R.
Lee Jeffrey R.
Schmidt P. Henry
Calkins Charles W.
Medical College of Georgia Research Institute Inc.
Rothschild Cynthia B.
Ungar Susan
LandOfFree
Screen for risk for gastric adenocarcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screen for risk for gastric adenocarcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screen for risk for gastric adenocarcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3361687